Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Editor's Comment

Editor's Comment 27. Koga T, Yano T, Ichikawa Y, Oizumi K, Mochizuki M. Pulmonary infiltrates re- 30. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: covered by FKS06 in a patient with Behc ¸et’s disease. Chest. 1993;104:309-311. response to topical treatment with tacrolimus. Br J Dermatol. 1999;140:338- 28. Abu-Elmagd K, Jegasothy BV, Ackerman CD, et al. Efficacy of FK 506 in the treat- 342. ment of recalcitrant pyoderma gangrenosum. Transplant Proc. 1991;23:3328- 31. Kang S, Lucky A, Pariser D, Lawrence I, Hanifin J, for the Tacrolimus Ointment 3329. Study Group. A long-term, noncomparative trial to evaluate the safety of topi- 29. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the cally applied tacrolimus as treatment of atopic dermatitis in pediatric patients. treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Poster presented at: the 58th Annual Meeting of the American Academy of Der- Am J Gastroenterol. 1997;92:876-879. matology; March 10-15, 2000; San Francisco, Calif. acrolimus is the first T-cell selective immunosuppressive agent with demonstrated topical applications. The Food and Drug Administra- T tion recently approved topical tacrolimus ointment with an indica- tion for treating atopic dermatitis in patients as young as age http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Editor's Comment

JAMA Dermatology , Volume 137 (4) – Apr 1, 2001

Editor's Comment

Abstract

27. Koga T, Yano T, Ichikawa Y, Oizumi K, Mochizuki M. Pulmonary infiltrates re- 30. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: covered by FKS06 in a patient with Behc ¸et’s disease. Chest. 1993;104:309-311. response to topical treatment with tacrolimus. Br J Dermatol. 1999;140:338- 28. Abu-Elmagd K, Jegasothy BV, Ackerman CD, et al. Efficacy of FK 506 in the treat- 342. ment of recalcitrant pyoderma gangrenosum. Transplant Proc. 1991;23:3328- 31....
Loading next page...
 
/lp/american-medical-association/editor-s-comment-ciQQWWp0Fq
Publisher
American Medical Association
Copyright
Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6068
eISSN
2168-6084
DOI
10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-137-4-dce00004
Publisher site
See Article on Publisher Site

Abstract

27. Koga T, Yano T, Ichikawa Y, Oizumi K, Mochizuki M. Pulmonary infiltrates re- 30. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: covered by FKS06 in a patient with Behc ¸et’s disease. Chest. 1993;104:309-311. response to topical treatment with tacrolimus. Br J Dermatol. 1999;140:338- 28. Abu-Elmagd K, Jegasothy BV, Ackerman CD, et al. Efficacy of FK 506 in the treat- 342. ment of recalcitrant pyoderma gangrenosum. Transplant Proc. 1991;23:3328- 31. Kang S, Lucky A, Pariser D, Lawrence I, Hanifin J, for the Tacrolimus Ointment 3329. Study Group. A long-term, noncomparative trial to evaluate the safety of topi- 29. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the cally applied tacrolimus as treatment of atopic dermatitis in pediatric patients. treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Poster presented at: the 58th Annual Meeting of the American Academy of Der- Am J Gastroenterol. 1997;92:876-879. matology; March 10-15, 2000; San Francisco, Calif. acrolimus is the first T-cell selective immunosuppressive agent with demonstrated topical applications. The Food and Drug Administra- T tion recently approved topical tacrolimus ointment with an indica- tion for treating atopic dermatitis in patients as young as age

Journal

JAMA DermatologyAmerican Medical Association

Published: Apr 1, 2001

There are no references for this article.